Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Intangibles (2023 - 2025)

Zevra Therapeutics' Intangibles history spans 3 years, with the latest figure at $6.4 million for Q4 2025.

  • For Q4 2025, Intangibles fell 90.69% year-over-year to $6.4 million; the TTM value through Dec 2025 reached $6.4 million, down 90.69%, while the annual FY2025 figure was $6.4 million, 90.69% down from the prior year.
  • Intangibles reached $6.4 million in Q4 2025 per ZVRA's latest filing, down from $6.7 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $69.2 million in Q4 2023 to a low of $2.0 million in Q2 2024.
  • Average Intangibles over 3 years is $25.8 million, with a median of $6.7 million recorded in 2025.
  • The largest YoY upside for Intangibles was 252.65% in 2025 against a maximum downside of 97.05% in 2025.
  • A 3-year view of Intangibles shows it stood at $69.2 million in 2023, then dropped by 0.34% to $69.0 million in 2024, then crashed by 90.69% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Intangibles are $6.4 million (Q4 2025), $6.7 million (Q3 2025), and $7.1 million (Q2 2025).